Who Paid My Doc
Megan Dieterich
Physician Assistant Washington, DC Physician Assistant
NPI 1114243482 CMS profile 10966074
1201 Sycamore Dr Se, Washington, DC 20032
General payments
$3,245
Research payments
$962
Ownership & investment interest
$0
Research they led as principal investigator
$409,865
Through program year 2025, Megan Dieterich of Washington, DC is reported in the CMS Open Payments database as having received $3,245 across 37 general payments and $962 in research payments paid to them. Separately, studies naming them as principal investigator received $409,865 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,932 | 18 | |
| 2024 | General | $373 | 6 | |
| 2024 | Research | $962 | 6 | |
| 2023 | General | $553 | 7 | |
| 2022 | General | $359 | 5 | |
| 2021 | General | $28 | 1 |
Beside peers
- Megan Dieterich
- Physician Assistant median
- Middle half of Physician Assistant
- National median
In program year 2025, general payments to Megan Dieterich were reported at $1,932. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.
Show as a table
| Year | Megan Dieterich | Physician Assistant median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $34 | $17–$122 | $163 |
| 2020 | $0 | $33 | $16–$78 | $114 |
| 2021 | $28 | $132 | $37–$438 | $132 |
| 2022 | $359 | $155 | $48–$522 | $149 |
| 2023 | $553 | $167 | $52–$557 | $160 |
| 2024 | $373 | $178 | $55–$600 | $164 |
| 2025 | $1,932 | $184 | $57–$620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 69 drugsPart D claims
2,379
Drug cost
$2,406,843
Branded share of claims
47%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 190 | $717,412 | |
| Tivicay Dolutegravir Sodium | Brand | 141 | $341,173 | |
| Cabenuva Cabotegravir/Rilpivirine | Brand | 33 | $199,489 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 48 | $170,903 | |
| Prezcobix Darunavir/Cobicistat | Brand | 67 | $159,533 | |
| Rukobia Fostemsavir Tromethamine | Brand | 16 | $153,625 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 31 | $137,651 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 59 | $129,668 | |
| Ozempic Semaglutide | Brand | 73 | $83,679 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 20 | $74,033 |
The 10 drugs with the highest cost, of 69 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| CABENUVA |
|
$145 | 33 | — |
| APRETUDE |
|
$8 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
43 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant in District of Columbia
Shana Perman
Physician Assistant · Washington, DC
Keriann Kuperman
Physician Assistant · Washington, DC
Harleen Bath
Physician Assistant · Washington, DC
Dustin Fronczak
Physician Assistant · Washington, DC
Irena Culic
Physician Assistant · Washington, DC
Catherine Uglietta
Physician Assistant · Washington, DC
Related records
Physician Assistant in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.